PD-1 저해제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향,예측(2025-2035년)
PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1706786
리서치사:Transparency Market Research
발행일:2025년 02월
페이지 정보:영문 242 Pages
라이선스 & 가격 (부가세 별도)
한글목차
PD-1 저해제 시장 - 조사 범위
TMR의 조사 리포트 '세계의 PD-1 저해제 시장'은 2025-2035년의 예측 기간에 시장의 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사하고 있습니다. 2025년을 기준연도, 2035년을 예측연도로서 2019-2035년의 세계 PD-1 저해제 시장의 매출과 예측을 제공합니다. 또한 2025-2035년의 세계 PD-1 저해제 시장의 연평균 성장률(CAGR %)도 게재하고 있습니다.
이 리포트는 광범위한 조사를 거쳐 작성되고 있습니다. 1차 조사에서는 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커에 대한 인터뷰를 시행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연차보고서, 프레스 릴리스, 관련 자료 등을 참조하여 PD-1 저해제 시장을 추측했습니다.
시장 스냅숏
2024년 시장 규모
414억 달러
2035년 시장 규모
2,015억 달러
CAGR
15.5%
세계의 PD-1 저해제 시장의 경쟁 구도에 대해 조사하고 있습니다. 세계의 PD-1 저해제 시장에서 사업을 운영하는 주요 기업이 식별되고, 각 기업이 다양한 속성에서 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT가 이 리포트에서 소개되고 있는 세계의 PD-1 저해제 시장에서 플레이어의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 개요 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계의 PD-1 저해제 시장 분석과 예측, 2020-2035년
제5장 주요 인사이트
주요 지역/국가에서의 규제 상황
PD-1 저해제 시장 동향
Porter's Five Forces 분석
PESTEL 분석
최종 용도에서의 주요 구입 지표
브랜드와 가격 분석
주요 업계 이벤트
국가·지역별 역학
제6장 세계의 시장 분석과 예측 : 약제 유형별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 약제 유형별, 2020-2035년
Pembrolizumab
Nivolumab
Cemiplimab
Dostarlimab
기타
의약품의 유형별 시장의 매력
제7장 세계의 시장 분석과 예측 : 적응증별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 적응증별, 2020-2035년
흑색종
호지킨 림프종
비소세포 폐암
신장암
두경부암
위암
기타
적응증별 시장의 매력
제8장 세계의 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
병원 약국
소매 약국
온라인 약국
유통 채널별 시장의 매력
제9장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
국가·지역별 시장의 매력
제10장 북미의 시장 분석과 예측
미국
캐나다
제11장 유럽의 시장 분석과 예측
독일
영국
프랑스
이탈리아
스페인
기타 유럽 지역
제12장 아시아태평양의 시장 분석과 예측
중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양
제13장 라틴아메리카의 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카 지역
제14장 중동 및 아프리카의 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제15장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024년)
기업 개요
Akeso Biopharma Co., Ltd.
Alphamab Oncology
Amgen Inc.
AstraZeneca
BeiGene LTD.
Bristol-Myers Squibb Company
Eli Lilly and Company.
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
GSK plc.
Innovent
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Merck & Co., Inc.
Eli Lilly and Company
Boehringer Ingelheim International GmbH.
Other prominent players
KSA
영문 목차
영문목차
PD-1 Inhibitor Drugs Market - Scope of Report
TMR's report on the global PD-1 inhibitor drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global PD-1 inhibitor drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PD-1 inhibitor drugs market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PD-1 inhibitor drugs market.
Market Snapshot
Market Value in 2024
US$ 41.4 Bn
Market Value in 2035
US$ 201.5 Bn
CAGR
15.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PD-1 inhibitor drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PD-1 inhibitor drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PD-1 inhibitor drugs market.
The report delves into the competitive landscape of the global PD-1 inhibitor drugs market. Key players operating in the global PD-1 inhibitor drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PD-1 inhibitor drugs market profiled in this report.
Key Questions Answered in Global PD-1 inhibitor drugs Market Report:
What is the sales/revenue generated by PD-1 inhibitor drugs across all regions during the forecast period?
What are the opportunities in the global PD-1 inhibitor drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global PD-1 inhibitor drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global PD-1 inhibitor drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PD-1 inhibitor drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global PD-1 Inhibitor Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, 2020-2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Landscape across Key Regions / Countries
5.2. PD-1 Inhibitor Drugs Market Trends
5.3. PORTER's Five Forces Analysis
5.4. PESTEL Analysis
5.5. Key Purchase Metrics for End-users
5.6. Brand and Pricing Analysis
5.7. Key Industry Events
5.8. Epidemiology by Country/Region
6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020-2035
6.3.1. Pembrolizumab
6.3.2. Nivolumab
6.3.3. Cemiplimab
6.3.4. Dostarlimab
6.3.5. Others
6.4. Market Attractiveness By Drug Type
7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2020-2035
7.3.1. Melanoma
7.3.2. Hodgkin Lymphoma
7.3.3. Non-Small Cell Lung Cancer
7.3.4. Kidney Cancer
7.3.5. Head and Neck Cancers
7.3.6. Stomach Cancer
7.3.7. Others
7.4. Market Attractiveness By Indication
8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2020-2035
10.2.1. Pembrolizumab
10.2.2. Nivolumab
10.2.3. Cemiplimab
10.2.4. Dostarlimab
10.2.5. Others
10.3. Market Value Forecast By Indication, 2020-2035
10.3.1. Melanoma
10.3.2. Hodgkin Lymphoma
10.3.3. Non-Small Cell Lung Cancer
10.3.4. Kidney Cancer
10.3.5. Head and Neck Cancers
10.3.6. Stomach Cancer
10.3.7. Others
10.4. Market Value Forecast By Distribution Channel, 2020-2035
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2020-2035
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2035
11.2.1. Pembrolizumab
11.2.2. Nivolumab
11.2.3. Cemiplimab
11.2.4. Dostarlimab
11.2.5. Others
11.3. Market Value Forecast By Indication, 2020-2035
11.3.1. Melanoma
11.3.2. Hodgkin Lymphoma
11.3.3. Non-Small Cell Lung Cancer
11.3.4. Kidney Cancer
11.3.5. Head and Neck Cancers
11.3.6. Stomach Cancer
11.3.7. Others
11.4. Market Value Forecast By Distribution Channel, 2020-2035
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country/Sub-region, 2020-2035
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2035
12.2.1. Pembrolizumab
12.2.2. Nivolumab
12.2.3. Cemiplimab
12.2.4. Dostarlimab
12.2.5. Others
12.3. Market Value Forecast By Indication, 2020-2035
12.3.1. Melanoma
12.3.2. Hodgkin Lymphoma
12.3.3. Non-Small Cell Lung Cancer
12.3.4. Kidney Cancer
12.3.5. Head and Neck Cancers
12.3.6. Stomach Cancer
12.3.7. Others
12.4. Market Value Forecast By Distribution Channel, 2020-2035
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country/Sub-region, 2020-2035
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2035
13.2.1. Pembrolizumab
13.2.2. Nivolumab
13.2.3. Cemiplimab
13.2.4. Dostarlimab
13.2.5. Others
13.3. Market Value Forecast By Indication, 2020-2035
13.3.1. Melanoma
13.3.2. Hodgkin Lymphoma
13.3.3. Non-Small Cell Lung Cancer
13.3.4. Kidney Cancer
13.3.5. Head and Neck Cancers
13.3.6. Stomach Cancer
13.3.7. Others
13.4. Market Value Forecast By Distribution Channel, 2020-2035
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2020-2035
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2035
14.2.1. Pembrolizumab
14.2.2. Nivolumab
14.2.3. Cemiplimab
14.2.4. Dostarlimab
14.2.5. Others
14.3. Market Value Forecast By Indication, 2020-2035
14.3.1. Melanoma
14.3.2. Hodgkin Lymphoma
14.3.3. Non-Small Cell Lung Cancer
14.3.4. Kidney Cancer
14.3.5. Head and Neck Cancers
14.3.6. Stomach Cancer
14.3.7. Others
14.4. Market Value Forecast By Distribution Channel, 2020-2035
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country/Sub-region, 2020-2035
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
